Pulmonary toxicity – a challenge for drug and chemical development

| March 11, 2020

article image
Despite the common assumption that adverse drug reactions only affect the kidney and liver, more than 600 medications inducing lung toxicity have been reported.1 Lungs are susceptible to toxicity due to their large surface area and metabolism of certain substances2, such as antibiotics and anti-inflammatories, and specialist drugs targeting the cardiovascular system and tumours. This has resulted in 4-10% of patients developing pulmonary toxicity.

Spotlight

Mallinckrodt Pharmaceuticals

As a specialty pharmaceuticals leader, we develop, manufacture, market and distribute specialty pharmaceuticals and therapies. Within our areas of focus, we provide treatments to underserved patient populations within neurology, rheumatology, nephrology, pulmonology, and ophthalmology. Our expertise also extends into acute and critical care hospital products, as well as our broad portfolio of generic prescription medicines, and active pharmaceutical ingredients. Together, we’re helping shape the future of the specialty pharmaceuticals industry by leveraging the values our founders instilled nearly 150 years ago quality, integrity and service.

OTHER ARTICLES
CHEMICAL TECHNOLOGY

The State of Intelligent Operations in Oil and Gas

Article | June 11, 2021

Intelligent Operations can play a vital role in creating connected content environments, however, many companies – especially within oil and gas – having been slow on the uptake. Businesses that implement digital transformation initiatives often gain a competitive advantage over their rivals, as they benefit from reductions in human error, increases in productivity and further support for compliance efforts.

Read More

CHEMICAL SPILL PREVENTION

Article | June 11, 2021

When it comes to your workplace, nothing should be prioritized over the safety of your employees. As your greatest asset to your business, they should feel safe in their work environment. Maintaining a safe work environment is a particularly important consideration for companies who work with or store hazardous materials. And it is not only critical for the appeasement of the Occupational Health and Safety Administration (OSHA) and the Environmental Protection Agency (EPA) requirements but the well-being and safety of your employees. That’s why, in this article, we will discuss chemical spill prevention in your workplace facility.

Read More

Chemical Accidents Lead To Increase In Investigations

Article | June 11, 2021

In the last two years, the U.S. Chemical Safety Board (CSB) has launched investigations into seven separate chemical accidents or explosions in the Houston area. Prior to 2018, the CSB only conducted roughly one investigation per year. Investigators believe that the massive increase in accidents which require an investigation by the CSB is due to a variety of factors such as the large number of chemical companies in the Houston area, the age of the infrastructure, and companies being allowed to self-regulate. Many of these explosions and fires have directly led to the deaths of workers, bystanders, millions of dollars in property damage, and the evacuation of tens of thousands of local residents who risk being exposed to toxic chemicals.

Read More

A Coordinated Approach to Chemical Reactivity

Article | June 11, 2021

Atoms are gregarious by nature, escaping a solitary existence by forming chemical bonds with their neighbors. Chemical reactivity, in turn, depends on the degree of atomic “isolation”; a lonely atom will more readily interact and form bonds with others, as compared to its more “coordinated” counterparts that are chemically engaged with other atoms. This coordination concept plays a central role in our understanding of chemical and catalytic activity. What has been lacking to date, however, is a direct and quantitative measurement of the variation in chemical reactivity of atoms having different degrees of coordination.

Read More

Spotlight

Mallinckrodt Pharmaceuticals

As a specialty pharmaceuticals leader, we develop, manufacture, market and distribute specialty pharmaceuticals and therapies. Within our areas of focus, we provide treatments to underserved patient populations within neurology, rheumatology, nephrology, pulmonology, and ophthalmology. Our expertise also extends into acute and critical care hospital products, as well as our broad portfolio of generic prescription medicines, and active pharmaceutical ingredients. Together, we’re helping shape the future of the specialty pharmaceuticals industry by leveraging the values our founders instilled nearly 150 years ago quality, integrity and service.

Events